MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

34.71 -1.64

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

34.02

Max

35.48

Schlüsselkennzahlen
By Trading Economics
Einkommen	-7.4M -81M
EPS	-0.5
Angestellte	205
EBITDA	-6.8M -79M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+32.94% upside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	3.7B 5.8B
Vorheriger Eröffnungskurs	36.35
Vorheriger Schlusskurs	34.71

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Jan. 2026, 22:45 UTC

Wichtige Markttreiber

GH Research Shares Up, Plans to Provide Update on New Drug Application

2. Jan. 2026, 22:13 UTC

Market Talk

Ergebnisse

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2. Jan. 2026, 21:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

2. Jan. 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2. Jan. 2026, 21:07 UTC

Ergebnisse

Tesla Stock Pops and Drops After Fourth-Quarter Deliveries. -- Barrons.com

2. Jan. 2026, 20:09 UTC

Market Talk

Oil Futures Slip in First Trading Day of the Year -- Market Talk

2. Jan. 2026, 19:48 UTC

Market Talk

U.S. Natural Gas Futures Kick Off 2026 With A Loss -- Market Talk

2. Jan. 2026, 18:53 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

2. Jan. 2026, 18:53 UTC

Market Talk

Mexico PMIs Show Manufacturing Weakness in December -- Market Talk

2. Jan. 2026, 17:56 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Meta's Manus Acquisition May Help Fill AI Monetization Gap -- Market Talk

2. Jan. 2026, 17:50 UTC

Market Talk

Apparel Industry Seen With Strength Across Income Levels -- Market Talk

2. Jan. 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

2. Jan. 2026, 16:33 UTC

Market Talk

Remittances to Mexico Fell 5.7% in November -- Market Talk

2. Jan. 2026, 16:18 UTC

Market Talk

Tesla Dethroned as World's Largest EV Maker -- Market Talk

2. Jan. 2026, 15:48 UTC

Ergebnisse

Software Has Been Battered by AI. Shopify, Veeva, and 3 More Stocks to Play a Turnaround. -- Barrons.com

2. Jan. 2026, 15:17 UTC

Market Talk

Tesla Expected to Make Its Switch to Robotics, AI in 2026 -- Market Talk

2. Jan. 2026, 15:01 UTC

Market Talk

Sable Seen Nearing Production Relaunch After Court Ruling -- Market Talk

2. Jan. 2026, 15:00 UTC

Ergebnisse

The Maker of Biscoff Cookies Bets on a Global Expansion -- WSJ

2. Jan. 2026, 14:56 UTC

Market Talk

Tesla's Sales Drop Was Better Than Feared -- Market Talk

2. Jan. 2026, 14:20 UTC

Market Talk

Capstone Copper's Mantoverde Strike Could Be Costly -- Market Talk

2. Jan. 2026, 14:20 UTC

Market Talk

Global Equities Roundup: Market Talk

2. Jan. 2026, 14:13 UTC

Market Talk

Oil Futures Open Year Lower on Oversupply Concerns -- Market Talk

2. Jan. 2026, 13:39 UTC

Market Talk

U.S. Natural Gas Futures Open Year Lower -- Market Talk

2. Jan. 2026, 13:01 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Unicredit Could Buy Delfin's BMPS Stake, Launch Full Takeover, Equita Says -- Market Talk

2. Jan. 2026, 12:45 UTC

Market Talk

Emerging-Market Dollar Bonds Record Strong Returns in 2025 -- Market Talk

2. Jan. 2026, 11:48 UTC

Market Talk

European Gas Climbs as Cold Weather Bites -- Market Talk

2. Jan. 2026, 11:36 UTC

Market Talk

Treasury Yields, Dollar Edge Higher as Near-Term Fed Rate Cut Looks Unlikely -- Market Talk

2. Jan. 2026, 11:30 UTC

Market Talk

Copper Rally Continues, Spurred by Supply Shocks -- Market Talk

2. Jan. 2026, 11:29 UTC

Market Talk

Dollar Rises After Posting Worst Year Since 2017 -- Market Talk

2. Jan. 2026, 11:15 UTC

Market Talk

Global Energy Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

32.94% Vorteil

12-Monats-Prognose

Durchschnitt 47.22 USD 32.94%

Hoch 67 USD

Tief 34 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.